A recent study reveals that patients who discontinue new GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who halt conventional lifestyle programs.
Research printed in a leading health publication demonstrates that while obese individuals can lose a large proportion of their body weight while undergoing treatment, the mass is regained at an estimated rate of nearly a kilo each month after stopping.
"Individuals buying these treatments must be aware of the potential of fast rebound weight gain when the medication ends," warns expert Dr. Susan Jebb.
That rate of regain means a reversion to pre-treatment weight within about a year and a half.
Comparing Approaches
The research, which reviewed 37 of studies involving thousands of participants, compared the effects of the injectable medications with older methods.
The team point out that individuals who lose weight through dieting typically experience a slower weight regain—approximately 100 grams monthly—once they finish.
Understanding the Fast Rebound
Experts propose the mechanism of the drugs is key to understanding the heightened regain.
These medications mimic a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Sustained high doses of the hormone concentrations several times higher than normal could lead to the body to produce less of its own natural GLP-1, and could diminish sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' means appetite is unsuppressed, making binge eating much more probable."
An Ongoing Issue?
The NHS suggest the injections for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
Many experts contend that, due to the likelihood of relapse, the treatment is often ongoing.
This opinion is echoed by drug manufacturers, who note that the findings "highlight the long-term character of excess weight," similar to managing conditions like high blood pressure.
User Experiences
People who have come off the medication report a intense return of hunger.
"It felt as if something activating and you're instantly extremely hungry," recalled one woman.
The struggle is compounded if individuals have not established lasting lifestyle or habit modifications during therapy.
Widespread Use
Recent estimates show that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with desire remaining high.
- Adoption is higher among females than men.
- The middle-aged age group shows the highest level of interest.
- A large proportion obtain the drugs through private healthcare rather than public health services.
Finally, clinicians stress that while the jabs are potent tools for weight loss, they are not a standalone fix and lasting health benefits likely depends on combined lifestyle management.
